HomeCategory

Oncology Archives - Page 3 of 5 - CubaHeal

AllAutoimmune & Neurological ConditionsCardiovascularChild DevelopmentCuba Travel & VisaCuba’s AchievementsCubaHeal NewsDermatologyEducationEndocrinologyGeriatricGynecologyInternational CollaborationMedical (General)NeurologyOncologyOphthalmologyOrthopedicPsychiatrySubstance Abuse RehabilitationTravel InsuranceUncategorized

Mechanism and positioning (context) Nimotuzumab is a humanized monoclonal antibody targeting EGFR. It has been developed and used in multiple countries for EGFR driven epithelial tumors and certain gliomas, typically as an add on to radiotherapy and or chemotherapy rather than as a standalone replacement for standard regimens. ScienceDirect 1) Effectiveness of Nimotuzuma 1.1 Head...

Scope note (freshness): This report prioritizes peer reviewed and registry sources available up to October 2023. Where a registry page has later administrative updates, the trial existence and design remain valid, but no post October 2023 outcomes are used. 1) Effectiveness of CIMAvax EGF Treatment 1.1 Overview and Mechanism CIMAvax EGF is a therapeutic cancer...

CIMAHER (NIMOTUZUMAB) SUMMARY OF PRODUCT CHARACTERISTICS

1. Medicinal Product Name CIMAher® (Nimotuzumab) 2. What This Medicine Is & What It Is Used For CIMAher® is a humanised monoclonal antibody that targets the Epidermal Growth Factor Receptor (EGFR), a protein that plays a key role in the growth of many solid tumours. By blocking EGFR activation, it helps slow or stop tumour...

Nimotuzumab is a cutting-edge monoclonal antibody therapy designed to treat various epithelial cancers, including head and neck cancer, glioma, and non-small cell lung cancer (NSCLC). Developed with advanced biotechnology, Nimotuzumab offers a targeted approach to cancer therapy, minimizing side effects while maximizing efficacy. This document explores Nimotuzumab’s mechanism, clinical outcomes, and benefits, underscoring its role...

Vaxira (Racotumomab) is an innovative therapeutic vaccine developed to treat non-small cell lung cancer (NSCLC). This groundbreaking therapy, originating from Cuban research, targets a specific cancer cell marker, offering a novel approach to treatment. This document delves into the scientific basis, clinical efficacy, and numerous benefits of Vaxira, highlighting its potential in revolutionizing cancer treatment....